Hilal Lashuel

photo placeholder image

Associate Professor

hilal.lashuel@epfl.ch +41 21 69 39691 http://lashuel-lab.epfl.ch

Citizenship : USA

Birth date : 15.01.1973

EPFL SV BMI LMNN
AI 2151 (Bâtiment AI)
Station 19
CH-1015 Lausanne

EPFL SV SSV-GE
AI 2151 (Bâtiment AI)
Station 19
CH-1015 Lausanne

perm_contact_calendarvCard
Administrative data

Publications

Infoscience

Research

Mission and Research Interest

Our Mission: To elucidate the molecular mechanisms underlying neurodegeneration in Alzheimer's and Parkinson's disease and develop novel strategies to facilitate the diagnosis, prevention and treatment of these diseases.

Our Research Goals 1. Elucidation of the relationship between the processes of protein misfolding and aggregation and neurodegeneration in Alzheimer’s disease (AD), Parkinson’s disease (PD) and related neurodegenerative disorders. 2. To understand the molecular mechanisms through which disease-associated variants and post-translational modification of the gene products associated with AD and PD induce neuronal dysfunction and neurodegeneration. 3. Develop novel therapeutic strategies based on modulating protein aggregation and clearance.

Research interest: Current research in the Lashuel laboratory focuses on applying chemical, biophysical, structural and molecular biology approaches to understanding the molecular and structural basis of protein misfolding and self-assembly and the mechanisms by which these processes contribute to the physiological and pathogenic properties of specific proteins implicated in neurodegenerative diseases. Current research efforts cover the following topics: (1) Elucidating the molecular and cellular determinants underlying amyloid-? and ?-synuclein aggregation and toxicity in Alzheimer’s diseases and Parkinson’s disease and related disorders. (2) Elucidating the structural basis of amyloid-associated toxicity by correlating the structural properties of defined aggregates in the amyloid pathway to their toxicity in primary neuronal cultures; (3) Developing innovative chemical approaches and novel tools to monitor and control protein folding/misfolding and self-assembly in vitro and in vivo with spatial and temporal resolution; (4) Understanding the role of post-translational modifications in the pathogenesis of neurodegenerative diseases; (5) Identifying and validating new therapeutic targets for treating Parkinson’s disease; (6) Developing novel therapeutic strategies to treat neurodegenerative diseases based on modulation of protein aggregation and clearance.

Research in the Lashuel lab is funded by several international funding agencies and foundations, including the Swiss National Science Foundation, European FP7 program (Marie Curie and ERC grants), Human Science Frontiers, Strauss Foundation, Cure the Huntington’s disease foundation and Michael J Fox foundation and is supported by collaborations with pharmaceutical and biotech companies (http://lashuel-lab.epfl.ch/page-50538-en.html), Nestle, Merck-Serono, AC Immune and Johnson and Johnson.